Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cost of Revenue: 2019-2025

Historic Cost of Revenue for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $22.7 million.

  • Catalyst Pharmaceuticals' Cost of Revenue rose 17.52% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 31.44%. This contributed to the annual value of $68.8 million for FY2024, which is 32.48% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Cost of Revenue is $22.7 million, which was up 9.90% from $20.6 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Cost of Revenue's 5-year high stood at $22.7 million during Q3 2025, with a 5-year trough of $4.5 million in Q2 2021.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Cost of Revenue value was $15.8 million (recorded in 2023), while the average stood at $16.5 million.
  • Data for Catalyst Pharmaceuticals' Cost of Revenue shows a peak YoY skyrocketed of 82.02% (in 2022) over the last 5 years.
  • Catalyst Pharmaceuticals' Cost of Revenue (Quarterly) stood at $7.3 million in 2021, then soared by 52.35% to $11.2 million in 2022, then soared by 41.21% to $15.8 million in 2023, then spiked by 36.90% to $21.6 million in 2024, then grew by 17.52% to $22.7 million in 2025.
  • Its Cost of Revenue was $22.7 million in Q3 2025, compared to $20.6 million in Q2 2025 and $17.9 million in Q1 2025.